Our study proposes a novel regulatory mechanism involving the transcription factor PPARG, which was predicted to be potentially responsible for the higher expression of TGFB1, VEGFA, and VEGFB in PBMC of LEAD patients compared to AAA subjects (Figure 6). This evidence concerns the gene VEGFA and triple-A syndrome.